Avon restructuring charges
This article was originally published in The Rose Sheet
Executive Summary
Firm will take $80 mil.-$90 mil. charge in Q4 "for costs to accelerate the company's business transformation initiatives" in light of lower than expected results in Latin American markets, Avon tells analysts Dec. 7. Company expects Q4 sales to increase in mid-single digits, boosted by U.S. revenues that are trending up 8%-9%. Additional restructuring charges are possible in 2002. Nevertheless, initiatives, coupled with "underlying strength of our business fundamentals, should enable Avon to deliver double-digit growth in earnings per share and local currency sales next year," firm predicts...
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.